Cubist’s Feverish Weekend: Rapid Response To Friday’s Cubicin “Approvable” Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm says its March 27 response to FDA clears up labeling issues related to infective endocarditis indication for daptomycin.